

10/511693

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****DT01 Rec'd PCT/PTC 14 OCT 2004**

Applicant(s): Masayuki AMAGAI, Takeji NISHIKAWA, and Manabu OHYAMA

Group Art Unit: TBA

Serial No.: TBA

Examiner: TBA

Filed: Herewith

For: DRUGS TO BE USED IN GENE THERAPY FOR RECESSIVELY TRANSMITTED  
GENETIC DISEASE**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to Rule 56, applicant hereby calls the attention of the Patent Office to the references listed on the attached Form PTO 1449. Copy(ies) of these eight (8) references ☒ are attached ☐ were filed in related application U.S. Serial No(s) \_\_\_\_\_, filed \_\_\_\_\_, respectively.

- ☐ This document is being filed within three (3) months of the filing date of the application
- ☐ A check for the requisite fee of \$180 is enclosed.
- ☒ This document is being concurrently filed with the above-identified application
- ☐ This document is being concurrently filed with an Request for Continued Examination (RCE)
- ☐ This document is being filed prior to a first Office Action
- ☒ This document is accompanied by a Search Report/Communication cited in a corresponding PCT or foreign counterpart application.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 4439-4026. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,  
MORGAN & FINNEGAN, L.L.P.

By: 

Evelyn M. Kwon  
Registration No. 54,246

Dated: October 14, 2004Correspondence Address:

MORGAN & FINNEGAN, L.L.P.  
3 World Financial Center  
New York, NY 10281  
(212) 415-8700 Telephone  
(212) 415-8701 Facsimile

Customer No.:

**27123**

DT01 Rec'd PCT/PTO 14 OCT 2001

<b>FORM PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION</b>	Attorney Docket: 4439-4026	Serial No: TBA <b>10/511693</b>
	Applicant: Masayuki AMAGAI, Takeji NISHIKAWA, and Manabu OHYAMA	
	Filing Date: HEREWITH	Group Art Unit: TBA

**U.S. PATENT DOCUMENTS**

Examiner Initial	Patent Number	Publication Date	Name	Class	Sub-Class	Filing Date

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Patent Number	Publication Date	Country	Class	Sub-Class	Translation
	WO 01/30383 A2	May 3, 2001	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 99/06562	February 11, 1999	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 98/30241	July 16, 1998	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	EP 1142473 A1	May 25, 2001	EPO			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 01/35733 A1	May 25, 2001	PCT			<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Abstract only
	2001-139496	May 22, 2001	JP			<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Abstract only
						<input type="checkbox"/> Yes <input type="checkbox"/> No
						<input type="checkbox"/> Yes <input type="checkbox"/> No

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)**

	Herzog, Roland W., et al. "Muscle-Directed Gene Transfer And Transient Immune Suppression Result In Sustained Partial Correction Of Canine Hemophilia B Caused By A Null Mutation", <i>Molecular Therapy</i> , 4(3): 192-200, September 2001.
	Fields, Paul A., et al. "Risk And Prevention Of Anti-Factor IX Formation In AAV-Mediated Gene Transfer In The Context Of A Large Deletion Of F9", <i>Molecular Therapy</i> , 4(3): 201-210, September 2001.

Examiner	Date Considered
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	